Shareholder Suit Targets Select Medical $16.50 Cash Deal With Executive-Led Consortium
Select Medical Holdings Corp.'s proposed sale to a consortium led by its executives and directors values the company at $16.50 per share in cash. The deal includes terms that could restrict superior competing bids and insiders may receive benefits not available to ordinary shareholders.
1. Transaction Overview
Select Medical has agreed to be acquired by a consortium led by its own executives and directors in a cash transaction valuing shares at $16.50 each. The deal structure grants the consortium exclusive negotiation rights and defines the timeline and closing conditions for the merger.
2. Insider Benefit and Offer Limitations
Under the current agreement, insiders stand to benefit directly from the sale execution, while terms grant the consortium the ability to reject superior bids, potentially discouraging third-party proposals. These stipulations raise concerns about equitable treatment of ordinary shareholders.
3. Shareholder Litigation
Halper Sadeh LLC is investigating potential breaches of fiduciary duty and federal securities laws, seeking increased consideration or additional disclosures on behalf of shareholders. Affected investors may pursue claims on a contingent fee basis without upfront legal expenses.